H.C. Wainwright adjusted the firm’s price target on NRx Pharmaceuticals to $19 from $2 and keeps a Buy rating on the shares following the 1-for-10 reverse stock split.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals announces alignment with FDA on study plan for NRX-100
- NRx Pharmaceuticals’ spinoff of Hope Therapeutics enabled by arbitration order
- NRx Pharmaceuticals publishes shareholder update letter
- NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
- NRx Pharmaceuticals to proceed with two new NDAs in 2024